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Although serial left ventricular ejection fraction and volumetric 
measurements using gated radionuclide angiography are com-
monly used to evaluate clinical changes and therapeutic outcomes 
in individual patients, criteria are not available for accurately 
interpreting whether a change in any of these hemodynamic 
measurements is clinically meaningful. Accordingly, the magni-
tude of inherent variability among sequential measurements of 
hemodynamic variables assessed by gated radionuclide angiogra-
phy was investigated in a double-bOOd placebo-controlled fashion 
in 39 patients during two placebo periods separated by 6 weeks. 
AU patients analyzed had remained clinically stable during the 
study period. 
Although the mean values for all hemodynamic variables 
between the two placebo periods were minimally changed, the 
dift'erences in individual patients were striking. Criteria were 
developed to allow meaningful interpretation of changes in hemo-
dynamic variables by estimating the likeUhood that an observed 
Left ventricular ejection fraction is a standard, commonly 
measured variable for assessing cardiac function and is the 
most powerful predictor of survival in patients after myocar-
dial infarction (1-4). Left ventricular volume measurements 
have been used for prospectively evaluating patients with 
acute myocardial infarction and deciding the proper timing 
for surgical intervention in patients with valvular heart 
disease on the basis of serial volumetric changes (4-10). 
Stroke volume and cardiac output are important variables 
for monitoring patients with congestive heart failure and 
assessing pharmacologic interventions (11-13). Further-
more, the peak systolic pressure/end-systolic volume ratio 
and its change from rest to exercise have been reported to be 
useful variables for, respectively, measuring left ventricular 
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change is due to variability alone. On the basis of this analysis 
of placebo radionuclide angiographic data, variation due to 
chance alone is unlikely to account for all variability if a change 
observed between the two rest gated studies in a patient is 
?:7% units for left ventricular ejection fraction, ?:45 mIIml for 
end-diastolic volume index, ?:35 mIIml for end-systolic volume 
index, ?:20 mIIm1 for stroke volume index and ?:1.25 liters/min 
per m1 for cardiac index. An observed 4% unit change in left 
ventricular ejection fraction (increase or decrease) after a medical 
intervention in an individual patient occurs by random variation 
>25% of the time. 
The criteria presented are applicable to clinical practice be-
cause they allow precise interpretation of hemodynamic changes 
measured by gated radionuclide angiography in individual pa-
tients whether the change is due to altered clinical status or to a 
medical intervention. 
(J Am Coll CardioI1991;18:112-9) 
contractility independent of loading conditions (14,15) and 
detecting myocardial ischemia during exercise (16-18). 
Although all of these variables can be directly measured 
during left and right heart catheterization, gated blood pool 
radionuclide angiography is an accurate noninvasive alter-
native method for assessing left ventricular hemodynamics 
(19,20). Despite the common clinical use of radionuclide 
angiography in assessing these measured and derived in-
dexes of left ventricular function, few data exist concerning 
the intrinsic short-term variability associated with these 
measurements (21-24). Defining the magnitude of variability 
inherent to this technique would facilitate a more clinically 
meaningful interpretation of therapeutic interventions or 
changes in a patient's clinical status. 
Many factors might contribute to differences in the results 
of two consecutive measurements of left ventricular hemo-
dynamic variables obtained with radionuclide angiography. 
A patient's clinical status may change or a therapeutic 
intervention may truly alter the measurements. However, 
other potentially large sources of variability include those 
intrinsic to performing the test and acquiring the image data, 
interobserver and intraobserver differences in processing the 
images and subclinical physiologic changes in a given pa-
0735-10971911$3.50 
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tient. Our goal was to define the absolute magnitude of 
variability from all sources associated with sequential radio-
nuclide angiographic measurements in patients without any 
perceptible change in clinical status. Accordingly, we report 
on the variability of gated radionuclide angiography utilizing 
a double-blind placebo-controlled study design in a clinically 
stable group of patients receiving placebo therapy who had 
two gated studies separated by a 6 week interval. 
Methods 
Study patients. The study group consisted of 39 patients 
(22 men, 17 women; mean age 56.5 ± 10.2 years, range 32 to 
79). All had frequent (2:30) ventricular premature beats/h 
during ambulatory electrocardiographic (ECG) monitoring 
and were enrolled in an arrhythmia trial comparing sotalol 
and quinidine. To ensure the absence of any drug effect 
when comparing the two placebo radionuclide angiograms, 
all rest and exercise studies were performed 2:20 half-lives 
after discontinuation of the antiarrhythmic drug. Cardiac 
diagnoses were ischemic heart disease in 20 patients, cardio-
myopathy in 4, mitral valve prolapse in 5, aortic regurgita-
tion in 1 patient and no known structural heart disease in 9 
patients. Nineteen patients had a prior history of myocardial 
infarction. 
Study design. This investigation was an ancillary study of 
a larger randomized, double-blind, placebo-controlled cross-
over trial (25) comparing the hemodynamic and antiarrhyth-
mic effects of sotalol and quinidine. This ancillary study was 
reviewed and approved by the Institutional Review Boards 
of Baylor College of Medicine and The Methodist Hospital. 
All patients signed a separate informed consent form in 
addition to consenting to the main trial. 
The study design has been previously published (25). 
Briefly, after an initial I week placebo period, all patients 
underwent both supine rest and exercise gated blood pool 
radionuclide angiography for assessment of left ventricular 
ejection fraction and volumes and cardiac output. Patients 
were then randomized for a 4 week period to either sotalo1 or 
quinidine, followed by a second 2 week placebo period. Rest 
and exercise gated studies were repeated near the end of this 
second placebo period when plasma levels of the preceding 
antiarrhythmic drug were documented to be zero. Patients 
were then crossed over to the other antiarrhythmic drug for 
an additional 4 weeks. Each radionuclide angiogram was 
read without knowledge of the treatment phase of the trial. 
To ensure that there were no carryover drug effects from 
the antiarrhythmic drugs, repeat radionuclide angiographic 
studies were performed only after patients had not taken the 
study drug for 2:20 half-lives. Furthermore, for inclusion in 
the analysis, patients had to remain clinically stable through-
out both placebo periods. Baseline medications were not 
altered in any patient after study entry to avoid potentially 
confounding drug effects on cardiac hemodynamics. Fur-
thermore, arrhythmia frequency did not differ significantly 
for patients between the two placebo periods. 
Assessment of cardiac hemodynamic variables. Rest and 
exercise gated radionuclide angiograms were obtained using 
a single crystal gamma camera equipped with a 0.5 in. 
(1.27 cm) sodium iodide crystal and a low energy paraIlel-
hole, all purpose collimator. The camera's energy discrimi-
nator was set on the 140 ke V photopeak of technetium-99m 
with a 20% window and data were acquired and processed 
with use of previously validated techniques and computer 
software (19). 
All patients received 25 to 30 mCi of technetium-99m 
after intravenous injection of stannous pyrophosphate for in 
vivo red cell labeling. The left anterior oblique projection 
with the "best septal" separation of the left and right 
ventricles was used for left ventricular ejection fraction and 
volume calculations. In six patients a 10° to 15° caudal tilt 
was utilized to best delineate the left ventricular borders; in 
these patients, it was used during both placebo studies. The 
gated studies were acquired on a 64 x 64 byte matrix for 
180 s using 24 frames/cardiac cycle. Although this acquisi-
tion time is relatively short compared with typical acquisi-
tion periods used for the gated technique, all studies had 
> 100,000 counts/frame with delineation of the left ventricu-
lar borders. A beat rejection algorithm was used during 
image acquisition to eliminate cardiac cycles with RR inter-
vals that differed by > 20% from the average cycle length, in 
addition to the next subsequent beat to avoid cardiac cycles 
with postextrasystolic potentiation. 
All patients underwent symptom-limited supine bicycle 
exercise beginning at 100 or 200 kp-m, with doubling of the 
work load at 3 min intervals. Each patient was exercised to 
an identical work load during both placebo studies. After the 
completion of cardiac imaging, a lead marker was placed 
over the left ventricle in the left anterior oblique projection 
and a 60 s static image was acquired in the anterior projec-
tion to determine left ventricular depth and correct for 
photon attenuation in the chest. Blood (5 m!) was taken from 
the contralateral arm of technetium-99m injection and 
counted for 60 s to determine the count rate per second per 
milliliter of blood. From the count rate and left ventricular 
depth information, counts were converted to milliliters of 
blood, allowing direct calculation of left ventricular end-
diastolic and end-systolic volumes. Stroke volume was ob-
tained by subtracting the end-systolic volume from the 
end-diastolic volume. Cardiac output was calculated by 
multiplying stroke volume by the heart rate. The peak 
systolic pressure/end-systolic volume index ratio was calcu-
lated from the manually acquired systolic blood pressure and 
the scintigraphically determined end-systolic volume index. 
The ratio of this value from rest to exercise was also 
calculated. All volume and cardiac output measurements 
were indexed to body surface area. Left ventricular volumes 
were measured by using a count-based technique that has 
been previously validated and reported from our laboratory 
(19). 
Data analyses. Cardiac imaging during both placebo pe-
riods was performed at the identical left anterior oblique 
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Table 1. Group Mean Hemodynamic Results in 39 Patients During Two Placebo Periods 
Placebo I Placebo 2 r Value 
Rest Ex Rest Ex Rest Ex 
LVEF (%) 46 ± 14 49 ± 15 47 ± 14* 50 ± 15 0.97 0.95 
EDVI (mllm2) 121 ± 52 117 ± 50 119 ± 41 118 ± 42 0.93 0.87 
ESVI (mllm2) 70 ± 48 64 ± 46 66 ± 41 62 ± 41 0.95 0.95 
SVI (mllm2) 51 ± 14 53 ± 18 52 ± II 55 ± 15 0.8\ 0.76 
CI (liters/min per m2) 3.4 ± 1.0 5.9 ± 2.0 3.6 ± 0.8 6.0 ± 1.8 0.80 0.7\ 
PSP/ESVI 2.9 ± 1.8 3.0 ± 1.8 3.6 ± 2.0 3.8 ± 2.4 0.93 0.9\ 
*p = 0.024 versus the first placebo period (placebo I). CI = cardiac index: EDVI = end-diastolic volume index; ESVI = end-systolic volume index; Ex = 
exercise; LVEF = left ventricular ejection fraction: PSP = peak systolic pressure: SVI = stroke volume index. 
angulation of the gamma camera for calculating left ventric-
ular ejection fraction and cardiac volumes. Image processing 
proceeded in the following manner. The end-diastolic and 
end-systolic frames for analysis were chosen on the basis of 
computer-calculated count rates over a manually drawn left 
ventricular area of interest. Nine point smoothing and back-
ground subtraction were performed as previously reported 
from our laboratory (19). The left ventricular ejection frac-
tion and volumes were then computer-derived from manu-
ally drawn areas of interest around the end-diastolic and 
end-systolic frames with use of a count -based technique (19). 
All studies were processed without knowledge of clinical or 
treatment data by a single experienced investigator to deter-
mine the magnitude of test variability between the two 
placebo studies for all hemodynamic variables. A second 
experienced investigator recalculated all ejection fraction 
measurements during the first placebo phase to provide an 
estimate of interobserver variability. 
Statistical analysis. Group hemodynamic variables during 
the two separate placebo periods were analyzed by paired t 
tests and linear regression. These data are expressed as 
mean values ± SD. A P value ::;0.05 was considered signif-
icant. 
Descriptive statistics were also generated for each of the 
individual hemodynamic variables of interest. However, 
because the magnitude of expected variation for the mea-
surements anticipated by chance alone was important, par-
ticular attention was paid to the development of confidence 
intervals for the change in an individual's measurement 
between the two placebo gated studies. Because attention 
was focused on the variability associated with these 
changes, Student's t test for paired analysis was performed. 
From this paired analysis, confidence interval widths for 
individual changes between the two placebo gated studies 
were generated. For example, the standard deviation of the 
difference between the two placebo left ventricular ejection 
fraction measurements (based on 39 patients) is 3.54% units. 
If the mean change in the ejection fraction is zero, the lower 
limit of the 95% confidence interval centered on zero is 
calculated as follows: 3.54 multiplied by the 2.5 percentile of 
a constant t random variable with 38 degrees of freedom. 
The resultant lower limit of the 95% confidence interval is 
then -7.33, whereas the upper limit is 7.33. The confidence 
interval width is 14.66. Therefore, given this confidence 
interval, a ?7% unit absolute change in left ventricular 
ejection fraction (either increase or decrease) is unlikely to 
be due to chance alone. 
In addition, probabilities based on a normal distribution 
were generated, assessing the likelihood that a given change 
in a measurement was based on chance alone. For example, 
the probability that a patient's ejection fraction will change 
by ?I % unit is equivalent to the probability that the absolute 
value of an observation from a normal distribution with 
mean of zero and a standard deviation of 3.54 is > I. This 
translates to the probability [(N(O,I)) > 0.277] = 0.779. 
Results 
Analysis of group hemodynamic data (Table 1). The anal-
ysis of mean group data for the two placebo periods showed 
no significant differences in rest (68 ± 10 vs. 70 ± 10 
beats/min) or exercise (111 ± 16 vs. 110 ± 20 beats/min) 
heart rate, respectively. Likewise. rest (133 ± 18 vs. 129 ± 
15 mm Hg) and exercise (166 ± 28 vs. 161 ± 28 mm Hg) 
systolic blood pressures and rest (84 ± to vs. 80 ± 9 mm Hg) 
and exercise (94 ± 14 vs. 92 ± 13 mm Hg) diastolic blood 
pressures were not significantly different between the two 
placebo periods. 
The mean values for both rest and exercise hemodynamic 
data during the two placebo intervals and their correlation 
coefficients are shown in Table 1. The mean baseline left 
ventricular ejection fraction for the group was 46 ± 14% 
(range 18% to 71%) with an ejection fraction <30% in 7 
patients, 30% to 39% in 6 patients, 40% to 49% in 6 patients 
and ?50% in the remaining 20 patients. None of the hemo-
dynamic variables (except rest ejection fraction) were signif-
icantly different between the two placebo periods and the 
correlation coefficients approached unity for the directly 
calculated variables of left ventricular ejection fraction, 
end-diastolic volume index and end-systolic volume index. 
Analysis of Individual Hemodynamic Data 
Ejection fraction (Table 2). Although the mean values for 
all measured and derived hemodynamic variables between 
the two placebo gated studies were unchanged, individual 
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Table 2. Confidence Limits for the Interpretation of Changes in 
Left Ventricular Ejection Fraction at Rest and During Supine 
Bicycle Exercise 
p Value* 
ALVEF (absolute%) Rest Exercise 
I 0.779 0.834 
2 0.575 0.674 
3 0.395 0.529 
4 0.258 0.401 
5 0.159 0.294 
6 0.091 0.208 
7 0.048 0.142 
8 0.024 0.093 
9 0.01l 0.059 
10 0.005 0.036 
*Probability that any observed change is due to random variatIOn. 
AL VEF = change observed in left ventricular ejection fraction between two 
radionuclide angiograms separated by 6 weeks. 
changes in some patients were marked. Most patients (90%) 
had a difference of :::;5% units in absolute rest ejection 
fraction between the two placebo studies, although individ-
ual patients showed greater variability. Confidence limits 
were calculated as described in the Statistical Analysis 
section for the interpretation of any observed change in rest 
or exercise ejection fraction between the two gated radionu-
elide angiograms (Table 2). On the basis of these calcula-
tions, an intervention resulting in a 7% unit change in rest or 
a 10% unit change in exercise ejection fraction is unlikely to 
occur as a result of chance alone. 
Cardiac volumes (Table 3). Eighty-four percent of pa-
tients had a :::;25 mllm2 change in end-diastolic volume index, 
whereas 81% had a difference of :::;15 mllm2 in end-systolic 
volume index between the two rest placebo measurements. 
Confidence limits for interpreting variability in end-diastolic 
and end-systolic volume indexes are listed in Table 3. An 
Table 3. Confidence Limits for the Interpretation of Changes in 
End-Diastolic and End-Systolic Volume Index at Rest and During 
Supine Bicycle Exercise 
p Value* p Value* 
AEDVI (ml/m") Rest Ex JlESVI (ml/m") Rest Ex 
5 0.810 0.849 5 0.741 0.741 
10 0.630 0.697 IO 0.516 0.503 
15 0.465 0.562 15 0.327 0.317 
20 0.332 0.441 20 0.194 0.184 
25 0.226 0.337 25 0.103 0.097 
30 0.147 0.246 30 0.051 0.046 
35 0.089 0.177 35 0.023 0.020 
40 0.052 0.124 40 0.009 0.008 
45 0.029 0.084 45 0.003 0.003 
50 0.016 0.054 50 0.001 0.001 
55 0.008 0.034 55 0.000 0.000 
*Probability that any observed change is due to random variation. A = 
change in a hemodynamic variable between two radionuclide angiograms 
separated by 6 weeks: other abbreviations as in Table I. 
Table 4. Confidence Limits for the Interpretation of Changes in 
Stroke Volume Index and Cardiac Index at Rest and During 
Supine Bicycle Exercise 
p Value* p Value* 
ASVI (ml/m") Rest Ex Ael (literslmin per m2) Rest Ex 
I 0.904 0.936 0.25 0.689 0.865 
5 0.542 0.674 0.50 0.430 0.734 
10 0.222 0.401 0.75 0.234 0.610 
15 0.066 0.208 1.00 0.112 0.497 
20 0.014 0.093 1.25 0.048 0.395 
25 0.002 0.035 1.50 0.017 0.312 
30 0.000 O.OIl 1.75 0.005 0.238 
2.00 0.002 0.177 
*Probabllity that any observed change is due to random variation. A = 
change: other abbreviations as In Table I. 
intervention resulting in a 45 mllm2 change in rest end-
diastolic volume index or a 35 mllm2 change in rest end-
systolic volume index is likely to represent a true patient 
change rather than variability in the radionuclide angio-
graphic technique. The corresponding exercise confidence 
limits for end-diastolic and end-systolic volume indexes are 
55 and 30 mllm2, respectively. 
Stroke volume and cardiac index (Table 4). Most patients 
(78%) had a difference of :::;10 mllm2 in absolute rest stroke 
volume index, whereas rest cardiac index showed greater 
variability. with only 62% of patients having a :::;0.5 liter/min 
per m2 change between the placebo periods. Confidence 
limits for interpreting variability in stroke volume and car-
diac indexes are presented in Table 4. Thus, changes of 2:20 
and 2:25 mllm2 for rest and exercise stroke volume index. 
respectively. are required to demonstrate a treatment effect, 
whereas even as great a change as I liter/min per m2 in rest 
and 2 liters/min per m2 in exercise cardiac index would not 
entirely dismiss random variability (even though all patients 
exercised to an identical work load both times). 
Systolic pressure/end-systolic volume index ratio (Table 5). 
The confidence limits for interpreting variability in the peak 
systolic pressure/end-systolic volume index ratio and the 
change in this ratio from rest to exercise are shown in Table 
5. A change of 2 in the rest peak systolic pressure/end-
systolic volume index ratio would be required to distinguish 
a real clinical change from random variability, whereas a 
change of 0.75 between the two gated radio nuclide angio-
grams would exceed variability for the exercise/rest ratio. 
For every hemodynamic variable with the exception of 
end-systolic volume index. the degree of change necessary 
to exclude random variation was greater for exercise than for 
rest data. Generally. confidence interval widths for various 
hemodynamic measurements were not dependent on dif-
ferent ranges of left ventricular ejection fraction. except for 
end-systolic volume index where the confidence interval 
width decreased with increasing ejection fraction. 
Individual hemodynamic data: interobserver analysis. In-
terobserver variability was determined for ejection fraction 
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Table 5. Confidence Limits for the Interpretation of Changes in 
Peak Systolic Pressure/End-Systolic Volume Index at Rest and 
During Supine Bicycle Exercise and the Ratio of Exercise to Rest 
Pressure-Volume Index 
p Value' 
dPSP/ESVI Rest Ex dERPV p Value* 
0.25 0.749 0.808 0.25 0.363 
0.50 0.516 0.627 0.50 0.077 
0.75 0.453 0.465 0.75 0.006 
1.00 0.317 0.332 1.00 0.000 
1.25 0.211 0.222 
1.50 0.134 0.144 
1.75 0.080 0.089 
2.00 0.046 0.051 
2.25 0.024 0.029 
2.50 0.012 0.015 
2.75 0.006 0.007 
3.00 0.003 0.004 
*Probability that any observed change is due to random variation. 
dERPV = change in the ratio of exercise to rest pressure volume index; other 
abbreviations as in Table I. 
through use of a second investigator who recalculated the 
value recorded for the first placebo study without knowledge 
of the results of the initial reading. The mean values for 
ejection fraction assessed by the two observers were similar 
(46 ± 14% vs. 46 ± 15%) and correlated well for the group 
(r = 0.95, p < 0.001). 
Discussion 
Variability of a test procedure. This study is the first to 
establish comprehensive criteria for interpreting short-term 
changes in both rest and exercise measurements of left 
ventricular systolic function and cardiac volumes obtained 
with gated radionuclide angiography. The 6 week interval 
between placebo radionuclide angiographic measurements 
used in this study of clinically stable patients does not 
describe all temporal variability. For instance, two studies 
obtained within a I week interval might result in less 
inherent variability. We believe, however, that the 6 week 
interval selected is a fair representation of short-term fol-
low-up periods commonly used in clinical practice. 
The results of this study emphasize the surprisingly large 
variability associated with radionuclide angiography, partic-
ularly when used to assess changes in exercise hemody-
namic variables. In this regard, the magnitude of change 
necessary to detect a real difference in hemodynamic varia-
bles over background variability may well exceed a clinically 
meaningful range. These data are a reminder that test results 
in clinical medicine should not always be categorically 
accepted at face value because an exact result is often 
implied (for example, left ventricular ejection fraction 38%), 
but is rarely true. The actual test result is a composite of a 
range of possible results, any of which may be the patient's 
true measurement. This range of results is often expressed as 
the variability of the procedure and can be statistically 
computed as a confidence interval. The correct interpreta-
tion of any test must therefore address the variability of the 
testing procedure itself and be assessed along with other 
relevant clinical data. 
Sources of variability. When two test results collected 
from the same patient are serially compared (for example, 
before and after an intervention or change in clinical status), 
this variability issue can become complex. A useful way to 
understand the nature of this issue is to divide variability into 
its two components. The first component is the systematic 
fraction, that is, some underlying important change in the 
patient's clinical status that has resulted in a change in the 
test value. This is the component of most concern to 
clinicians. In our trial, we attempted to minimize this com-
ponent as much as possible by studying only patients who 
were judged to be clinically stable by weekly history and 
physical assessment. Despite these safeguards, subclinical 
changes in individual patient hemodynamics may have oc-
curred and contributed to the total observed variability. The 
second component is the focus of this investigation; the 
variability introduced by various aspects of the testing itself 
or the random component. The clinician's response to the 
test result must take both sources of variation into account. 
This is impossible to do when the potential size of the 
random component is unknown. Once the size of this 
random or chance component is estimated, it becomes easier 
to assess the change in the test result and thus address the 
question: Is the change an important one? 
In this study, it was not possible to determine the relative 
contribution of each individual source of test variability to 
the sum total. Rather, we addressed the more practical 
clinical issue of how background variability from whatever 
source would affect the interpretation of hemodynamic in-
formation acquired by gated radio nuclide angiography in 
clinically stable individual patients. The 6 week follow-up 
period chosen for this study is within the time frame com-
monly used in routine clinical practice and clinical trials to 
assess short-term changes in a patient's clinical status before 
and after a therapeutic intervention. 
Factors influencing the magnitude of individual variability 
with radionuclide angiography. The results of this trial have 
practical relevance considering that gated radionuclide angi-
ography is a commonly used technique for temporally as-
sessing the results of medical interventions or changes in the 
clinical status of individual patients. Interpretation of such 
observed changes could be greatly misleading to the clinician 
unaware of the variability inherent to the technique. Com-
mon clinical situations where these criteria might be useful 
include assessing the results of therapy for congestive heart 
failure (11-13) or the results of thrombolytic therapy after 
acute myocardial infarction (26-30). The data presented in 
this study provide guidance for interpreting individual 
changes observed in measured as well as derived hemody-
namic variables. The criteria developed from these data 
should represent the "best case scenario" for the gated 
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technique, in that all studies were acquired by qualified 
nuclear technologists from one laboratory, processed on one 
piece of equipment and analyzed by a single experienced 
nuclear cardiologist. Although the observed variability might 
have been less if only patients with a stable cardiac rhythm 
had been studied, the confounding variable of ventricular 
ectopic activity was circumvented with the use of an effec-
tive beat rejection algorithm. Furthermore, although study 
acquisition times were relatively short (180 s), all of the 
cardiac images had reasonable count statistics for evaluating 
ejection fraction and left ventricular volumes. In this regard, 
confidence interval widths might be even broader than the 
ones generated in the present study if gated radionuclide 
angiography was performed in a multicenter clinical trial, 
given the large assortment of technologists acquiring data, 
the mUltiple types of equipment used and the many physi-
cians asked to interpret the studies. 
In this trial, only the data of patients who remained 
clinically stable throughout the study protocol were ana-
lyzed. The two placebo-controlled radio nuclide angiograms 
were acquired under double-blind conditions; that is, the 
interpreting nuclear cardiologist did not know whether the 
studies were acquired during placebo or an active drug 
phase. Weekly clinic visits included interval history and 
physical examinations and all medications were held con-
stant throughout the 6 week study period. Clearly, ejection 
fraction and cardiac volumes are highly dependent on heart 
rate and cardiac loading conditions. Although left ventricular 
end-diastolic pressure was not directly measured in this 
study, heart rate and blood pressure were not significantly 
different between the two placebo periods. Therefore, to the 
extent practically possible, confounding variables were min-
imized. 
Confidence limits for ejection fraction, ventricular vol-
umes, stroke output and cardiac index. On the basis of our 
data analysis, variation due to chance alone is unlikely if an 
observed change between two rest radionuclide angiograms 
is 2:.7% units for ejection fraction, 2:.45 mllm2 for end-
diastolic volume index, 2:.35 mllm2 for end-systolic volume 
index, ;::20 ml/m2 for stroke volume index and 2:.1.25 liters/ 
min per m2 for cardiac index. These confidence limits are 
applicable to the wide range of ejection fraction values (18% 
to 71%) observed in our study patients. Our data are too 
sparse, however, to adequately describe changes in patients 
with an ejection fraction <20%. The directly calculated 
values of ejection fraction and end-diastolic and end-systolic 
volume indexes had smaller confidence interval widths than 
the derived values of stroke volume index and cardiac index; 
the latter derived values probably had larger confidence 
interval widths because their variability is a composite of the 
variability inherent in each of the directly calculated varia-
bles. All exercise variables except for end-systolic volume 
index showed greater random variation than the rest values 
despite image acquisition during both placebo studies at the 
same work loads and exercise times. In fact, for exercise 
cardiac index, even a change of 2 liters/min per m2 between 
two consecutive radionuclide angiographic studies could 
have been due to chance alone, casting great doubt on any 
clinical utility of this derived variable measured during 
exercIse. 
Factors potentially responsible for the greater random 
variation in exercise compared with rest hemodynamic var-
iables might include 1) a greater disparity between the two 
placebo studies in the temporal increase in heart rate and 
blood pressure to peak exercise values coupled with the 
scintigraphic image acquisition over a 3 min period; 2) chest 
motion during exercise causing distortion of image quality; 
and 3) less desirable count statistics in exercise compared 
with rest images. 
Comparison with previous studies. Previous investigators 
(21-24) have reported limited data for interpreting variability 
in left ventricular ejection fraction and volumes using gated 
radionuclide angiography. Wackers et al. (21) reported on 
the intraobserver differences between two gated studies 
performed on the same day in 41 patients and 1 to 5 days 
apart in 29 patients; 23 of 70 patients had a ;::5% unit change 
in absolute percent ejection fraction from the first to the 
second study compared with 8 of 39 patients in the present 
study. Cornyn et aJ. (22) investigated the variability associ-
ated with gated radionuclide angiography during both rest 
and exercise, but their study was limited to patients with 
aortic regurgitation and left ventricular dilation. Keough et 
aJ. (24) studied 17 patients with serial gated radionuclide 
angiography who had a markedly depressed ejection fraction 
(mean 18%) and were awaiting cardiac transplantation. The 
intraobserver and interobserver reproducibilies for deter-
mining ejection fraction were both ±3% units. The 95% 
confidence interval of ±8% units in their study is similar to 
the ±7% unit confidence interval in our report. None of 
these earlier studies, however, developed criteria to calcu-
late the confidence limits for interpreting any level of ejec-
tion fraction change. For instance, on the basis of the 
present study, an observed 4% unit absolute change in rest 
left ventricular ejection fraction (increase or decrease) after 
a therapeutic intervention will occur by chance alone> 25% 
of the time. The present study is the first to provide 
confidence interval widths for changes in rest/exercise left 
ventricular volumes as well as derived variables (stroke 
volume and cardiac indexes). Tables 2 to 5 facilitate rapid 
interpretation of a broad range of "observed treatment 
effects" in a given patient. 
Importance of individual variability to clinical investiga-
tion. In addition to providing simple criteria for interpreting 
whether an observed change indicates a true therapeutic 
effect. this study highlights potential pitfalls in evaluating 
certain radionuclide angiographic results of clinical trials. In 
trials such as those assessing thrombolytic therapy for acute 
myocardial infarction (26-30), the effects of vasodilator and 
inotropic therapy for congestive heart failure (11-13) or the 
negative inotropic effects of antiarrhythmic drugs (25), mean 
group changes in left ventricular ejection fraction and vol-
ume measurements are the end points most commonly 
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assessed. When a parallel placebo serial group is available 
for comparison, interpretation of group mean data remains 
valid because the variability attributed to the technique 
should be randomly distributed across both groups. How-
ever, if one were to assess ejection fraction or volumetric 
changes in individual patients rather than the group, the 
importance of spontaneous variability would have to be 
considered in the context of these confidence limit tables. 
Although the present investigation utilized a crossover study 
design to assess the spontaneous variability of radionuclide 
angiography in individual patients, the confidence limits 
generated could also be applied to assess individual changes 
in patients entered into a parallel placebo-controlled study 
when an initial baseline radionuclide angiogram is acquired. 
An example from one of our previously published (30) 
parallel placebo-controlled trials assessing the effects of 
intracoronary streptokinase in acute myocardial infarction 
(for which we had access to all raw data) is instructive. In 
this randomized study, the patients who achieved vessel 
patency with intracoronary streptokinase had an improved 
left ventricular ejection fraction (42 ± 17% increasing to 
49 ± 16%; p = 0.023) over 7 to 10 days, whereas the mean 
ejection fraction in the control group did not change (48 ± 
12% vs. 50 ± 11%). The probabilities generated in the 
present study establish that a change of 2:7% units in rest 
ejection fraction for an individual patient is unlikely to occur 
by chance alone. Using this criterion, only 7 (44%) of the 16 
patients achieving patency after intracoronary streptokinase 
would have increased their ejection fraction above the 
threshold for variability. Thus, unequivocal benefit in the 
streptokinase group occurred in 7 of 16 patients. 
Interpretation of an observed improvement in group 
mean rest left ventricular ejection fraction of 2% or 3% units 
in a large thrombolytic trial may be statistically significant; 
however, the extent to which this represents a clinical 
benefit or is a reasonable mortality surrogate is not estab-
lished. Perhaps a prospectively defined change in ejection 
fraction above the background variability applied to each 
randomized patient in a clinical trial would be a more 
accurate barometer of improved survival. Knowledge of the 
confidence limits for interpreting any individual change in 
different variables of left ventricular systolic function and 
volumes is crucial to such an analysis. 
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